BR112022003633A2 - Métodos para produção de arginase 1 recombinante humana e usos da mesma - Google Patents
Métodos para produção de arginase 1 recombinante humana e usos da mesmaInfo
- Publication number
- BR112022003633A2 BR112022003633A2 BR112022003633A BR112022003633A BR112022003633A2 BR 112022003633 A2 BR112022003633 A2 BR 112022003633A2 BR 112022003633 A BR112022003633 A BR 112022003633A BR 112022003633 A BR112022003633 A BR 112022003633A BR 112022003633 A2 BR112022003633 A2 BR 112022003633A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- recombinant human
- producing recombinant
- arginase
- human arginase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2221/00—Applications of separation devices
- B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
métodos para produção de arginase 1 recombinante humana e usos da mesma. são descritos métodos para produzir arginase recombinante, tal como arginase 1 humana recombinante substituída por cobalto, peguilada. também são descritas composições farmacêuticas compreendendo tal arginase recombinante, bem como métodos de tratamento e usos de tal arginase recombinante
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962894319P | 2019-08-30 | 2019-08-30 | |
PCT/US2020/048536 WO2021041904A1 (en) | 2019-08-30 | 2020-08-28 | Methods for production of human recombinant arginase 1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003633A2 true BR112022003633A2 (pt) | 2022-06-07 |
Family
ID=72433097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003633A BR112022003633A2 (pt) | 2019-08-30 | 2020-08-28 | Métodos para produção de arginase 1 recombinante humana e usos da mesma |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210189371A1 (pt) |
EP (1) | EP4022052A1 (pt) |
JP (1) | JP2022545738A (pt) |
KR (1) | KR20220082813A (pt) |
CN (1) | CN114729344A (pt) |
AU (1) | AU2020335905A1 (pt) |
BR (1) | BR112022003633A2 (pt) |
CA (1) | CA3149592A1 (pt) |
IL (1) | IL290817A (pt) |
MX (1) | MX2022002437A (pt) |
TW (1) | TW202122409A (pt) |
WO (1) | WO2021041904A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114350698B (zh) * | 2021-11-30 | 2023-07-18 | 新泰市佳禾生物科技有限公司 | 人重组精氨酸酶i生产菌及其构建方法 |
WO2023201228A1 (en) * | 2022-04-11 | 2023-10-19 | Aeglea Biotherapeutics, Inc. | Treatment of arginase 1 deficiency |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3778885T (lt) * | 2008-10-31 | 2023-06-12 | Aerase, Inc. | Dirbtinai sukurtų žmogaus arginazių kompozicijos ir vėžio gydymo metodai |
WO2011008495A2 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
WO2012061015A2 (en) * | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
CN105112391B (zh) * | 2015-09-22 | 2018-07-06 | 浙江道尔生物科技有限公司 | 一种人源精氨酸酶突变体及其制备方法和用途 |
HRP20220406T1 (hr) * | 2016-08-08 | 2022-05-27 | Aerase, Inc. | Pripravci i metode za liječenje raka deplecijom arginina i imunoonkološkim sredstvima |
TW201910513A (zh) * | 2017-08-16 | 2019-03-16 | 香港商鎧耀波麗堂(香港)有限公司 | 胺基酸耗竭治療的組合物及方法 |
KR20200122298A (ko) * | 2017-12-05 | 2020-10-27 | 에어레이즈, 인크. | 아르기나제 1 결핍을 치료하기 위한 방법 및 조성물 |
WO2021257523A1 (en) * | 2020-06-15 | 2021-12-23 | Aeglea Biotherapeutics, Inc. | Use of arginase for treatment of influenza infections |
-
2020
- 2020-08-28 CN CN202080060999.2A patent/CN114729344A/zh active Pending
- 2020-08-28 JP JP2022513535A patent/JP2022545738A/ja active Pending
- 2020-08-28 WO PCT/US2020/048536 patent/WO2021041904A1/en active Application Filing
- 2020-08-28 TW TW109129594A patent/TW202122409A/zh unknown
- 2020-08-28 EP EP20768844.1A patent/EP4022052A1/en active Pending
- 2020-08-28 CA CA3149592A patent/CA3149592A1/en active Pending
- 2020-08-28 US US17/006,383 patent/US20210189371A1/en not_active Abandoned
- 2020-08-28 AU AU2020335905A patent/AU2020335905A1/en active Pending
- 2020-08-28 BR BR112022003633A patent/BR112022003633A2/pt unknown
- 2020-08-28 KR KR1020227010296A patent/KR20220082813A/ko active Search and Examination
- 2020-08-28 MX MX2022002437A patent/MX2022002437A/es unknown
-
2022
- 2022-02-22 IL IL290817A patent/IL290817A/en unknown
-
2023
- 2023-06-20 US US18/338,255 patent/US20240110172A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210189371A1 (en) | 2021-06-24 |
US20240110172A1 (en) | 2024-04-04 |
TW202122409A (zh) | 2021-06-16 |
KR20220082813A (ko) | 2022-06-17 |
JP2022545738A (ja) | 2022-10-28 |
MX2022002437A (es) | 2022-06-02 |
CN114729344A (zh) | 2022-07-08 |
WO2021041904A1 (en) | 2021-03-04 |
CA3149592A1 (en) | 2021-03-04 |
EP4022052A1 (en) | 2022-07-06 |
AU2020335905A1 (en) | 2022-03-10 |
IL290817A (en) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
ECSP14016014A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
BR112018004078A2 (pt) | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo | |
CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
BR112014017780A8 (pt) | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos | |
BR112018001292A2 (pt) | métodos para melhor liberação de agentes ativos a tumores | |
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
BR112018070189A2 (pt) | método para seleção de proteínas recombinantes ricas em m6p | |
BR112022007710A2 (pt) | Composições farmacêuticas de albumina e rapamicina | |
BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
BR112022003633A2 (pt) | Métodos para produção de arginase 1 recombinante humana e usos da mesma | |
CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
EA202192555A1 (ru) | Комбинированная терапия для лечения рака |